Navigation Links
Poniard Pharmaceuticals Announces Upcoming Conference Participation
Date:8/27/2008

SOUTH SAN FRANCISCO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that Jerry McMahon, Ph.D., chairman and CEO, will participate in three upcoming conferences in September during which he will provide a corporate overview, including a discussion of the clinical development program for picoplatin, the Company's lead product candidate.

-- The Thomas Weisel Partners Healthcare Conference on Wednesday, September 3, at 4:25 p.m. Eastern Time at the Four Seasons Hotel in Boston

-- BioCentury's NewsMakers in the Biotech Industry Conference on Thursday, September 4, at 2:30 p.m. Eastern Time at the Millennium Broadway Hotel in New York

-- The 3rd Annual Citi Biotech Day on Monday, September 8, at 2:35 p.m. Eastern Time at the Citi Center in New York

Live audio webcasts of Poniard's presentations at the Thomas Weisel Partners Healthcare Conference and Citi Biotech Day will be available for 10 business days following each conference. Each webcast can be accessed on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors,
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IL (PRWEB) January 15, 2014 Look ... find hard-working items for the lab, from fluid handling ... Guaranteed-in-Stock (GIS)—ready to ship when you order. , ... Peristaltic Pumps , from the L/S® model for precise ...
(Date:1/15/2014)... This webinar will focus on EMA and FDA ... biosimilars. , Regulatory frameworks are evolving many countries to ... complex nature of biopharmaceuticals makes the demonstration of biosimilarity ... Based on the specific aspects of biosimilar drug development ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains ... these latent viruses is the Epstein Barr Virus (EBV), and ... (RA) is a chronic inflammatory disease that destroys the body’s ... RA patients have high concentrations of EBV DNA in their ...
(Date:1/15/2014)... January 15, 2014 AudioNotch is the ... therapy for the treatment of tinnitus. Patients listen to ... and over a period of weeks to months, their tinnitus ... in two forms: Notched Music and Notched White Noise. Now, ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced ... pursue a pivotal (Phase II/III) randomized trial ... refractory,patients with head and neck cancers. The ... by the Company,s Board of Directors from ...
... team up in specialty biologics development, TORONTO ... and,Therapure BioPharma Inc. have agreed to partner in ... for cancer treatments, with a goal of,advancing the ... a,marketing partner to add to its portfolio of ...
... deCODE,genetics (Nasdaq: DCGN ) today announced today that ... Qualifications Panel to present a plan for,regaining compliance ... market value of listed securities of $50 million. ... Letter from The,Nasdaq Stock Market LLC indicating that ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial 2Therapure Biopharma Inc. announces collaboration with BioVectra Inc. 2deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter 2deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter 3deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter 4
(Date:4/17/2014)... RIVERSIDE, Calif. One day about eight years ago, ... of California, Riverside, and her father were on a field ... stumbled upon an orchid they had never seen before. , ... authority on orchids. The orchid turned out to be ... Silveras: Lophiaris silverarum . , "Lophiaris" is the genus ...
(Date:4/17/2014)... in France have hit on a novel method ... the correct and most effective treatment possible., Kidney ... western and developing world. If left untreated, apart ... renal failure and other complications. In many patients ... Clearly a more effective pathological approach to diagnosis ...
(Date:4/17/2014)... whereby the genetic information of DNA is used ... have numerous different functions in living organisms. Messenger ... gene expression, by relating the genetic information of ... proteins. , By examining the different types ... organism at a given time, researchers can determine ...
Breaking Biology News(10 mins):Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3Rapid and accurate mRNA detection in plant tissues 2
... discovery by researchers at Oregon State University, the world,s multi-billion ... This industry, that produces metal castings used in everything from ... dates back thousands of years to before Greek and Roman ... but still continues to evolve. Some modern technologies use ...
... sites across the U.S. have contaminated groundwater that requires remediation, ... meaning restoration is unlikely to be achieved in the next ... new report from the National Research Council. The report ... sites ranges from $110 billion to $127 billion, but the ...
... becomes increasingly important to know in detail the dynamics of ... of a millimeter). What happens, for example, when we try ... molecules, such as DNA) through a nanopore if knots cause ... because now a new DNA sequencing method to electrochemically analyze ...
Cached Biology News:Sweet new approach discovered to help produce metal casting parts, reduce toxicity 2Report: Cleanup of some contaminated groundwater sites unlikely for decades 2Report: Cleanup of some contaminated groundwater sites unlikely for decades 3Pull with caution 2
Although each Beacon 2000 System includes one preinstalled sample chamber (size specified at time of order), optional chambers are available and easily retrofit by the user....
... Immunogen : Recombinant human ... 5mg/ml BSA, 0.15M NaCl, 0.05% ... of glycerol to 30% Quality ... on acid extracts of murine ...
cDNA Size Fractionation Columns offer an efficient and convenient method for size-fractioning double-stranded cDNA....
Self Closing Forceps...
Biology Products: